This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Hepatitis
  • /
  • Reversal of NASH fibrosis with pharmacotherapy.

Reversal of NASH fibrosis with pharmacotherapy.

Read time: 1 mins
Published:31st Aug 2019
Author: Alukal JJ, Thuluvath PJ.
Availability: Pay for access, or by subscription
Ref.:Hepatol Int. 2019;13(5):534-545.
NAFLD is a spectrum of liver disease starting with fatty liver at one end of the spectrum and cirrhosis or liver cancer at the other end. Worldwide, NAFLD has become one of the most common liver diseases and it has also become one of the leading indications for liver transplantation. Our understanding of the NAFLD epidemiology, pathogenesis and its progression to cirrhosis has improved over the last 2 decades. Currently, however, there are no FDA-approved treatment options for fibrosis resulting from NAFLD. A number of compounds targeting multiple pathways involved in the progression of NAFLD are currently in phase 2-3 trials. In this review, we will briefly discuss the epidemiology, the pathogenesis and the current status of treatment of NAFLD.

Read abstract on library site

Access full article